Table 1.
baseline characteristics of the study population
| Characteristics | Number | Percentage (%) |
|---|---|---|
| Infant characteristics | ||
| Median age in months (IQR) | 1.5 (1.5-2.0) | |
| Final outcome | ||
| Discharged negative | 342 | 93.7 |
| HIV infected | 10 | 2.7 |
| Died | 13 | 3.6 |
| Gender | ||
| Female | 162 | 44.4 |
| Male | 203 | 55.6 |
| Timelines of enrolment | ||
| Within 2 months | 317 | 86.8 |
| Beyond 2 months | 48 | 13.2 |
| Type of treatment facility | ||
| Private not-for-profit | 164 | 44.9 |
| Public health facility | 201 | 55.1 |
| Nevirapine prophylaxis | ||
| Yes | 360 | 98.6 |
| No | 5 | 1.4 |
| Timing of nevirapine | ||
| Within 72 hours | 356 | 98.9 |
| After 72 hours | 2 | 0.55 |
| Unknown timing | 2 | 0.55 |
| Duration of exclusive breastfeeding | ||
| ≥ 6 months | 100 | 27.4 |
| ˂ 6 months | 221 | 60.5 |
| Unknown | 44 | 12.1 |
| Total duration of breastfeeding | ||
| ≥ 12 months | 310 | 84.9 |
| ˂ 12 months | 15 | 4.1 |
| Unknown | 40 | 11.0 |
| Maternal baseline characteristics | ||
| Mean CD4 (SD)* | 592.94 (360.56) | |
| CD4 Count: | 133 | 36.5 |
| >500cells/ml | 107 | 29.3 |
| <500cells/ml | 125 | 34.2 |
| Viral Load (VL) | ||
| ≤1000cps/ml | 39 | 10.7 |
| ≥1000cps/m | 5 | 1.4 |
| HIV diagnosis | ||
| Before pregnancy | 231 | 63.3 |
| In antenatal/postpartum | 134 | 36.7 |
| ART initiation | ||
| Before pregnancy | 203 | 55.6 |
| In antenatal/postpartum | 162 | 44.4 |
*
SD=Standard deviation